Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

EASD 2024

Keep up to date with the top stories from the 60th EASD Annual Meeting with our congress hub page.
ADVANCED SEARCH
Log in
Top
Targeted Oncology
Published in:

10-08-2024 | Pancreatic Cancer | Review Article

Identifying Actionable Alterations in KRAS Wild-Type Pancreatic Cancer

Authors: Ahmed Elhariri, Jaydeepbhai Patel, Himil Mahadevia, Douaa Albelal, Ahmed K. Ahmed, Jeremy C. Jones, Mitesh J. Borad, Hani Babiker

Published in: Targeted Oncology | Issue 5/2024

Login to get access

Abstract

The 5-year relative survival rate for pancreatic cancer is currently the lowest among all cancer types with a dismal 13%. A Kirsten rat sarcoma virus (KRAS) gene mutation is present in approximately 90% of patients with pancreatic cancer; however, KRAS-specific drugs are not yet widely used in clinical practice for pancreatic cancer, specifically the KRASG12D variant. Advances in genomic testing revealed an opportunity to detect genetic alterations in a subset of patients with no KRAS mutation termed KRAS wild-type. Patients with KRAS wild-type tumors have a propensity to express driver alterations, hence paving the way for utilizing a targeted therapy approach either via clinical trials or standard-of-care drugs. These alterations include fusions, amplifications, translocations, rearrangements and microsatellite instability-high tumors and can be as high as 11% in some studies. Here, we discuss some of the most notable alterations in KRAS wild-type and highlight promising clinical trials.
Literature
1.
2.
3.
Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25.PubMedCrossRef
4.
Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691–703.CrossRef
5.
Wainberg ZA, Melisi D, Macarulla T, Pazo Cid R, Chandana SR, De La Fouchardière C, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet. 2023;402(10409):1272–81.PubMedCrossRef
6.
7.
Strickler JH, Satake H, George TJ, Yaeger R, Hollebecque A, Garrido-Laguna I, et al. Sotorasib in KRAS pG12C-mutated advanced pancreatic cancer. N Engl J Med. 2022;388(1):33–43.PubMedPubMedCentralCrossRef
8.
Singhi AD, George B, Greenbowe JR, Chung J, Suh J, Maitra A, et al. Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers. Gastroenterology. 2019;156(8):2242-53.e4.PubMedCrossRef
9.
Bailey P, Chang DK, Nones K, Johns AL, Patch A-M, Gingras M-C, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531(7592):47–52.PubMedCrossRef
10.
Buscail L, Bournet B, Cordelier P. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2020;17(3):153–68.PubMedCrossRef
11.
12.
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–4.PubMedCrossRef
13.
Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269): l1.CrossRef
14.
Philip PA, Azar I, Xiu J, Hall MJ, Hendifar AE, Lou E, et al. Molecular characterization of KRAS wild-type tumors in patients with pancreatic adenocarcinoma. Clin Cancer Res. 2022;28(12):2704–14.PubMedPubMedCentralCrossRef
15.
Topham JT, Tsang ES, Karasinska JM, Metcalfe A, Ali H, Kalloger SE, et al. Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma. Nat Commun. 2022;13(1):5941.PubMedPubMedCentralCrossRef
16.
Mehdi M, Szabo A, Shreenivas A, Thomas JP, Tsai S, Christians KK, et al. Chemotherapy-free treatment targeting fusions and driver mutations in KRAS wild-type pancreatic ductal adenocarcinoma, a case series. Ther Adv Med Oncol. 2024;16:17588359241253112.PubMedPubMedCentralCrossRef
17.
Singh H, Keller RB, Kapner KS, Dilly J, Raghavan S, Yuan C, et al. Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer. Clin Cancer Res. 2023;29(22):4627–43.PubMedPubMedCentralCrossRef
18.
19.
Loo E, Khalili P, Beuhler K, Siddiqi I, Vasef MA. BRAF V600E mutation across multiple tumor types: correlation between DNA-based sequencing and mutation-specific immunohistochemistry. Appl Immunohistochem Mol Morphol. 2018;26(10):709–13.PubMedCrossRef
20.
Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene. 2007;26(22):3279–90.PubMedCrossRef
21.
22.
23.
Hendifar A, Blais EM, Wolpin B, Subbiah V, Collisson E, Singh I, et al. Retrospective case series analysis of RAF family alterations in pancreatic cancer: real-world outcomes from targeted and standard therapies. JCO Precis Oncol. 2021;5:1325–38.CrossRef
24.
Seghers AK, Cuyle PJ, Van Cutsem E. Molecular targeting of a BRAF mutation in pancreatic ductal adenocarcinoma: case report and literature review. Target Oncol. 2020;15(3):407–10.PubMedCrossRef
25.
Sasankan S, Rebuck L, Darrah G, Harari Turquie M, Rabinowitz I. Metastatic pancreatic cancer with BRAF and P53 mutations: case report of therapeutic response to doublet targeted therapy. Case Rep Oncol. 2020;13(3):1239–43.PubMedPubMedCentralCrossRef
26.
Butt SU, Mejias A, Morelli C, Torga G, Happe M, Patrikidou A, et al. BRAF/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series. Cancer Chemother Pharmacol. 2021;87(3):437–41.PubMedCrossRef
27.
Salama AKS, Li S, Macrae ER, Park JI, Mitchell EP, Zwiebel JA, et al. Dabrafenib and trametinib in patients with tumors with BRAF(V600E) mutations: results of the NCI-MATCH trial subprotocol H. J Clin Oncol. 2020;38(33):3895–904.PubMedPubMedCentralCrossRef
28.
Subbiah V, Kreitman RJ, Wainberg ZA, Gazzah A, Lassen U, Stein A, et al. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nat Med. 2023;29(5):1103–12.PubMedPubMedCentralCrossRef
29.
Wen PY, Stein A, van den Bent M, De Greve J, Wick A, de Vos FYFL, et al. Dabrafenib plus trametinib in patients with BRAF/V600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncol. 2022;23(1):53–64.PubMedCrossRef
30.
Ross JS, Wang K, Chmielecki J, Gay L, Johnson A, Chudnovsky J, et al. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. Int J Cancer. 2016;138(4):881–90.PubMedCrossRef
31.
Gkountakos A, Singhi AD, Westphalen CB, Scarpa A, Luchini C. Fusion genes in pancreatic tumors. Trends Cancer. 2024;10(5):430–43.PubMedCrossRef
32.
Ciner AT, Jiang Y, Hausner P. BRAF-driven pancreatic cancer: prevalence, molecular features, and therapeutic opportunities. Mol Cancer Res. 2023;21(4):293–300.PubMedCrossRef
33.
Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, et al. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol. 2018;36(6):536–42.PubMedCrossRef
34.
Chmielecki J, Hutchinson KE, Frampton GM, Chalmers ZR, Johnson A, Shi C, et al. Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes. Cancer Discov. 2014;4(12):1398–405.PubMedCrossRef
35.
Chen CC, Feng W, Lim PX, Kass EM, Jasin M. Homology-directed repair and the role of BRCA1, BRCA2, and related proteins in genome integrity and cancer. Annu Rev Cancer Biol. 2018;2:313–36.PubMedCrossRef
36.
37.
Ben-Ammar I, Rousseau A, Nicolle R, Tarabay A, Boige V, Valery M, et al. Precision medicine for KRAS wild-type pancreatic adenocarcinomas. Eur J Cancer. 2024;197: 113497.PubMedCrossRef
38.
Jia X, Wang K, Xu L, Li N, Zhao Z, Li M. A systematic review and meta-analysis of BRCA1/2 mutation for predicting the effect of platinum-based chemotherapy in triple-negative breast cancer. Breast. 2022;66:31–9.PubMedPubMedCentralCrossRef
39.
Emelyanova M, Pudova E, Khomich D, Krasnov G, Popova A, Abramov I, et al. Platinum-based chemotherapy for pancreatic cancer: impact of mutations in the homologous recombination repair and Fanconi anemia genes. Ther Adv Med Oncol. 2022;14:17588359221083050.PubMedPubMedCentralCrossRef
40.
41.
Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015;33(3):244–50.PubMedCrossRef
42.
Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381(4):317–27.PubMedPubMedCentralCrossRef
43.
O’Reilly EM, Lee JW, Zalupski M, Capanu M, Park J, Golan T, et al. Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation. J Clin Oncol. 2020;38(13):1378–88.PubMedPubMedCentralCrossRef
44.
Terrero G, Datta J, Dennison J, Sussman DA, Lohse I, Merchant NB, et al. Ipilimumab/nivolumab therapy in patients with metastatic pancreatic or biliary cancer with homologous recombination deficiency pathogenic germline variants. JAMA Oncol. 2022;8(6):1–3.PubMedCrossRef
45.
Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R. The FGFR landscape in cancer: analysis of 4853 tumors by next-generation sequencing. Clin Cancer Res. 2016;22(1):259–67.PubMedCrossRef
46.
Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5):671–84.PubMedPubMedCentralCrossRef
47.
Goyal L, Saha SK, Liu LY, Siravegna G, Leshchiner I, Ahronian LG, et al. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov. 2017;7(3):252–63.PubMedCrossRef
48.
Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med. 2023;388(3):228–39.PubMedCrossRef
49.
Sootome H, Fujita H, Ito K, Ochiiwa H, Fujioka Y, Ito K, et al. Futibatinib is a novel irreversible FGFR 1–4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors. Cancer Res. 2020;80(22):4986–97.PubMedCrossRef
50.
Subbiah V, Sahai V, Maglic D, Bruderek K, Touré BB, Zhao S, et al. RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations. Cancer Discov. 2023;13(9):2012–31.PubMedPubMedCentralCrossRef
51.
Poon D, Tan MH, Khor D. Stage 4 pancreatic adenocarcinoma harbouring an FGFR2-TACC2 fusion mutation with complete response to erdafitinib a pan-fibroblastic growth factor receptor inhibitor. BMJ Case Rep. 2021;14(9): e244271.PubMedPubMedCentralCrossRef
52.
Ng CF, Glaspy J, Placencio-Hickok VR, Thomassian S, Gong J, Osipov A, et al. Exceptional response to erdafitinib in FGFR2-mutated metastatic pancreatic ductal adenocarcinoma. J Natl Compr Canc Netw. 2022;20(10):1076–9.PubMedCrossRef
53.
Helal C, Valéry M, Ducreux M, Hollebecque A, Smolenschi C. FGFR2 fusion in metastatic pancreatic ductal adenocarcinoma: is there hope? Eur J Cancer. 2022;176:168–70.PubMedCrossRef
54.
Stein L, Reeser JW, Wing MR, Murugesan K, Paruchuri A, Risch Z, et al. Abstract 3395: clinical impact of FGFR inhibitors on FGFR2 positive pancreatic cancer. Cancer Res. 2023;83(7 Suppl.):3395.CrossRef
55.
56.
Singhi AD, Ali SM, Lacy J, Hendifar A, Nguyen K, Koo J, et al. Identification of targetable ALK rearrangements in pancreatic ductal adenocarcinoma. J Natl Compr Canc Netw. 2017;15(5):555–62.PubMedCrossRef
57.
Gower A, Golestany B, Gong J, Singhi AD, Hendifar AE. Novel ALK fusion, PPFIBP1-ALK, in pancreatic ductal adenocarcinoma responsive to alectinib and lorlatinib. JCO Precis Oncol. 2020;4:865–70.CrossRef
58.
Ou K, Liu X, Li W, Yang Y, Ying J, Yang L. ALK rearrangement-positive pancreatic cancer with brain metastasis has remarkable response to ALK inhibitors: a case report. Front Oncol. 2021;11: 724815.PubMedPubMedCentralCrossRef
59.
Parejo-Alonso B, Royo-García A, Espiau-Romera P, Courtois S, Curiel-García Á, Zagorac S, et al. Pharmacological targeting of the receptor ALK inhibits tumorigenicity and overcomes chemoresistance in pancreatic ductal adenocarcinoma. Biomed Pharmacother. 2023;158: 114162.PubMedCrossRef
60.
Adashek JJ, Sapkota S, de Castro LR, Seiwert TY. Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma. Precis Oncol. 2023;7(1):36.CrossRef
61.
Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19(12):1654–67.PubMedCrossRef
62.
Dagogo-Jack I, Brannon AR, Ferris LA, Campbell CD, Lin JJ, Schultz KR, et al. Tracking the evolution of resistance to ALK tyrosine kinase inhibitors through longitudinal analysis of circulating tumor DNA. JCO Precis Oncol. 2018;2:1–14.
63.
Jonna S, Feldman RA, Swensen J, Gatalica Z, Korn WM, Borghaei H, et al. Detection of NRG1 gene fusions in solid tumors. Clin Cancer Res. 2019;25(16):4966–72.PubMedPubMedCentralCrossRef
64.
Fernandez-Cuesta L, Thomas RK. Molecular pathways: targeting NRG1 fusions in lung cancer. Clin Cancer Res. 2015;21(9):1989–94.PubMedCrossRef
65.
Jones MR, Lim H, Shen Y, Pleasance E, Ch’ng C, Reisle C, et al. Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer. Ann Oncol. 2017;28(12):3092–7.PubMedCrossRef
66.
Gay ND, Wang Y, Beadling C, Warrick A, Neff T, Corless CL, et al. Durable response to afatinib in lung adenocarcinoma harboring NRG1 gene fusions. J Thorac Oncol. 2017;12(8):e107–10.PubMedCrossRef
67.
Jones MR, Williamson LM, Topham JT, Lee MKC, Goytain A, Ho J, et al. NRG1 gene fusions are recurrent, clinically actionable gene rearrangements in KRAS wild-type pancreatic ductal adenocarcinoma. Clin Cancer Res. 2019;25(15):4674–81.PubMedCrossRef
68.
Schram AM, O’Reilly EM, O’Kane GM, Goto K, Kim D-W, Neuzillet C, et al. Efficacy and safety of zenocutuzumab in advanced pancreas cancer and other solid tumors harboring NRG1 fusions. J Clin Oncol. 2021;39(15 Suppl.):3003.CrossRef
69.
Odintsov I, Lui AJW, Sisso WJ, Gladstone E, Liu Z, Delasos L, et al. The anti-HER3 mAb seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with oncogenic NRG1 fusions. Clin Cancer Res. 2021;27(11):3154–66.PubMedPubMedCentralCrossRef
70.
Kim D-W, Schram AM, Hollebecque A, Nishino K, Macarulla T, Rha DY, et al. The phase I/II eNRGy trial: zenocutuzumab in patients with cancers harboring NRG1 gene fusions. Future Oncol. 2024;20(16):1057–67.PubMedCrossRef
71.
Liu SV, Frohn C, Minasi L, Fernamberg K, Klink AJ, Gajra A, et al. Real-world outcomes associated with afatinib use in patients with solid tumors harboring NRG1 gene fusions. Lung Cancer. 2024;188: 107469.PubMedCrossRef
72.
Amit M, Na’ara S, Fridman E, Vladovski E, Wasserman T, Milman N, et al. RET, a targetable driver of pancreatic adenocarcinoma. Int J Cancer. 2019;144(12):3014–22.PubMedCrossRef
73.
Kato S, Subbiah V, Marchlik E, Elkin SK, Carter JL, Kurzrock R. RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients. Clin Cancer Res. 2017;23(8):1988–97.PubMedCrossRef
74.
Subbiah V, Wolf J, Konda B, Kang H, Spira A, Weiss J, et al. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial. Lancet Oncol. 2022;23(10):1261–73.PubMedCrossRef
75.
76.
Manea CA, Badiu DC, Ploscaru IC, Zgura A, Bacinschi X, Smarandache CG, et al. A review of NTRK fusions in cancer. Ann Med Surg (Lond). 2022;79: 103893.PubMedPubMedCentral
77.
Pishvaian MJ, Garrido-Laguna I, Liu SV, Multani PS, Chow-Maneval E, Rolfo C. Entrectinib in TRK and ROS1 fusion-positive metastatic pancreatic cancer. JCO Precis Oncol. 2018;2:1–7.PubMedCrossRef
78.
Hyman D, Tan DSW, van Tilburg C, Albert C, Geoerger B, Farago A, et al. 365O: durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer. Ann Oncol. 2019;30: ix123.CrossRef
79.
Yun KM, Narezkina A, Redfern C, Velasco K, Bazhenova L. Repotrectinib in a patient with NTRK fusion-positive pancreatic carcinoma and congenital long QT syndrome. JCO Precis Oncol. 2024;8: e2300265.PubMedCrossRef
80.
Solomon BJ, Drilon A, Lin JJ, Bazhenova L, Goto K, De Langen J, et al. 1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: update from the phase I/II TRIDENT-1 trial. Ann Oncol. 2023;34:S787–8.CrossRef
81.
Nagasaka M, Zhang SS, Baca Y, Xiu J, Nieva J, Vanderwalde A, et al. Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing. BMC Cancer. 2023;23(1):1000.PubMedPubMedCentralCrossRef
82.
Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371(21):1963–71.PubMedPubMedCentralCrossRef
83.
Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trials. Lancet Oncol. 2020;21(2):261–70.PubMedCrossRef
84.
Drilon A, Camidge DR, Lin JJ, Kim S-W, Solomon BJ, Dziadziuszko R, et al. Repotrectinib in ROS1 fusion-positive non-small-cell lung cancer. N Engl J Med. 2024;390(2):118–31.PubMedCrossRef
85.
86.
Latham A, Srinivasan P, Kemel Y, Shia J, Bandlamudi C, Mandelker D, et al. Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer. J Clin Oncol. 2019;37(4):286–95.PubMedCrossRef
87.
Bonneville R, Krook MA, Kautto EA, Miya J, Wing MR, Chen H-Z, et al. Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol. 2017;1:1–15.CrossRef
88.
Luchini C, Brosens LAA, Wood LD, Chatterjee D, Shin JI, Sciammarella C, et al. Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications. Gut. 2021;70(1):148–56.PubMedCrossRef
89.
Chakrabarti S, Bucheit L, Starr JS, Innis-Shelton R, Shergill A, Dada H, et al. Detection of microsatellite instability-high (MSI-H) by liquid biopsy predicts robust and durable response to immunotherapy in patients with pancreatic cancer. J Immunother Cancer. 2022;10(6): e004485.PubMedPubMedCentralCrossRef
90.
Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1–10.PubMedCrossRef
91.
Coston T, Desai A, Babiker H, Sonbol MB, Chakrabarti S, Mahipal A, et al. Efficacy of immune checkpoint inhibition and cytotoxic chemotherapy in mismatch repair-deficient and microsatellite instability-high pancreatic cancer: Mayo Clinic experience. JCO Precis Oncol. 2023;7: e2200706.PubMedCrossRef
92.
O’Connor CA, Harrold E, Lin Y-T, Walch HS, Gazzo A, Kane SR, et al. Somatic mismatch repair deficiency in pancreas cancer (PC): immune checkpoint blockade (ICB) outcomes and exploratory genomic analyses. J Clin Oncol. 2024;42(16 Suppl.):4144.CrossRef
93.
Schultheis B, Reuter D, Ebert MP, Siveke J, Kerkhoff A, Berdel WE, et al. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study. Ann Oncol. 2017;28(10):2429–35.PubMedCrossRef
94.
Qin S, Li J, Bai Y, Wang Z, Chen Z, Xu R, et al. Nimotuzumab plus gemcitabine for K-Ras wild-type locally advanced or metastatic pancreatic cancer. J Clin Oncol. 2023;41(33):5163–73.PubMedCrossRef
95.
Cecchini M, Sklar J, Lacy J. EGFR exon 19 deletion in pancreatic adenocarcinoma responds to erlotinib, followed by T790M-mediated resistance. J Natl Compr Canc Netw. 2017;15(9):1085–9.PubMedCrossRef
96.
Park R, Al-Jumayli M, Miller K, Saeed A, Saeed A. Exceptional response to erlotinib monotherapy in EGFR exon 19-deleted, KRAS wild-type, chemo-refractory advanced pancreatic adenocarcinoma. Cancer Treat Res Commun. 2021;27: 100342.PubMedCrossRef
97.
Jardim DL, Schwaederle M, Wei C, Lee JJ, Hong DS, Eggermont AM, et al. Impact of a biomarker-based strategy on oncology drug development: a meta-analysis of clinical trials leading to FDA approval. J Nat Cancer Instit. 2015;107(11): djv253.CrossRef
98.
Wagle N, Grabiner BC, Van Allen EM, Hodis E, Jacobus S, Supko JG, et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 2014;4(5):546–53.PubMedPubMedCentralCrossRef
99.
Peters S, Michielin O, Zimmermann S. Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma. J Clin Oncol. 2013;31(20):e341–4.PubMedCrossRef
100.
Munoz J, Schlette E, Kurzrock R. Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a BRAF mutation. J Clin Oncol. 2013;31(20):e351–2.PubMedCrossRef
101.
102.
Mangat PK, Halabi S, Bruinooge SS, Garrett-Mayer E, Alva A, Janeway KA, et al. Rationale and design of the targeted agent and profiling utilization registry study. JCO Precis Oncol. 2018;2:1–14.CrossRef
Metadata
Title
Identifying Actionable Alterations in KRAS Wild-Type Pancreatic Cancer
Authors
Ahmed Elhariri
Jaydeepbhai Patel
Himil Mahadevia
Douaa Albelal
Ahmed K. Ahmed
Jeremy C. Jones
Mitesh J. Borad
Hani Babiker
Publication date
10-08-2024
Publisher
Springer International Publishing
Published in
Targeted Oncology / Issue 5/2024
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI
https://doi.org/10.1007/s11523-024-01088-3

Other articles of this Issue 5/2024

Targeted Oncology 5/2024 Go to the issue

Original Research Article

Safety and Preliminary Efficacy of Once-Weekly Split-Dose Selinexor in Soft Tissue Sarcoma: Results of the Phase Ib METSSAR Clinical Trial

Original Research Article

lnsights into Adjuvant Systemic Treatment Selection for Patients with Stage III Melanoma: Data from the Dutch Cancer Registry

Original Research Article

Pembrolizumab in Patients with Advanced Urothelial Carcinoma with ECOG Performance Status 2: A Real-World Study from the ARON-2 Project

Original Research Article

A Phase 1a/1b Dose Escalation/Expansion Study of the Anti-PD-1 Monoclonal Antibody Nofazinlimab in Chinese Patients with Solid Tumors or Lymphoma

Review Article

Malignant Peripheral Nerve Sheath Tumor, a Heterogeneous, Aggressive Cancer with Diverse Biomarkers and No Targeted Standard of Care: Review of the Literature and Ongoing Investigational Agents

Letter to the Editor

Comment on: “Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta‑analysis”
Image Credits